Key facts
- Verdot’s last known valuation is $68.7M (Jul 2022).
- It has raised $10.4M; the latest was PE Growth/Expansion ($10.4M) in Jan 2025.
- Notable investors include SWEN Capital Partners, Caisse d'Epargne, Lauxera Capital Partners, BioProcess360, Capital Export — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Verdot
- ·The full record, as it builds
Funding rounds
No funding rounds for Verdot are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Verdot
Manufacturer of purification equipment intended for the bio-pharmacy, cosmetology and food industries. The company uses critical technology for the development and production of active ingredients for drugs, vaccines and biotechnological products for pharmaceutical clients.
- Sector
- Business Products and Services (B2B)
- HQ
- Riom, France
- Founded
- 1950
- Employees
- 63
- Website
- verdot-biotechnologies.com/
- Ownership
- Privately Held (backing)
Verdot doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verdot shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verdot in its N-PORT filings yet. We sweep new filings monthly.